[Screening and prevention of toxic optic neuropathies due to anti-mycobacterium therapies: proposal of recommendations].
Orssaud C, Nguyen DT, Rouzaud C, Pavie J, Pinot J, Lortholary O, Bremond-Gignac D, Robert MP.
J Fr Ophtalmol. 2022 May;45(5):495-503. doi: 10.1016/j.jfo.2021.08.016. Epub 2022 Apr 13.
Risk factors for type-1 reactions in borderline leprosy patients.
Roche PW, Theuvenet WJ, Britton WJ.
Lancet. 1991 Sep 14;338(8768):654-7. doi: 10.1016/0140-6736(91)91232-j.
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M, Saul A, Estrada-Parra S, Estrada-Garcia I.
Int Arch Allergy Immunol. 1998 May;116(1):60-6. doi: 10.1159/000023926.
Immunohistological studies of skin biopsies from patients with lepromatous leprosy.
Mshana RN, Humber DP, Belehu A, Harboe M.
J Clin Immunol. 1983 Jan;3(1):22-9. doi: 10.1007/BF00919135.
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum.
Scollard DM, Bhoopat L, Kestens L, Vanham G, Douglas JT, Moad J.
Clin Immunol Immunopathol. 1992 Jun;63(3):230-6. doi: 10.1016/0090-1229(92)90227-f.
A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
Garraud O, Ribierre O, Bach MA.
Int J Lepr Other Mycobact Dis. 1986 Mar;54(1):38-45.
